Handbook of HER2-targeted agents in breast cancer [electronic resource] /
Alvarez, Ricardo H.author.
Cortés, Javier.author.
Mattos-Arruda, Leticia.author.
Falzon, Mary.author.
Fasolo, Angelica.author.
Gandy, Michael.author.
Gianni, Luca.author.
Harbeck, Nadia.author.
Piccart, Martine.author.
Zambelli, Stefania.author.
Zardavas, Dimitrios.author.
Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year.  Of these cases, approximately  15-25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes.  However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies. Handbook of HER2-Targeted Agents in Breast Cancer  provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings.
Description based upon print version of record.
Includes bibliographical references.
Introduction and background biology -- HER2 testing -- HER2-positive breast cancer: adjuvant and neoadjuvant therapy -- HER2-positive metastatic breast cancer: first-line treatment -- HER2-positive metastatic breast cancer: second-line treatment -- Emerging targeted agents for HER2-positive breast cancer.
Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year.  Of these cases, approximately  15-25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes.  However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies. Handbook of HER2-Targeted Agents in Breast Cancer  provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings.
Oncology  .
Primary care (Medicine).
General practice (Medicine).
Internal medicine.
Pharmacotherapy.
Oncology.
Primary Care Medicine.
General Practice / Family Medicine.
Internal Medicine.
Pharmacotherapy.